How (re)insurers deal with weight-loss drugs
Source: Middle East Insurance Review | Feb 2025
Insurers are no doubt closely monitoring the evolving landscape of development and the usage of weight-loss drugs. Despite the current high costs and unknown long-term unknown factors, they can be a valuable tool in tackling the projected increase of obesity, says Swiss Re’s Ms Natalie Kelly.
Archived articles are available to Magazine subscribers only.
For Full Access to
the magazine
SUBSCRIBE here.